Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TT8FYO9)

• DTT Name: Platelet-derived growth factor receptor alpha (PDGFRA) DTT Info
• Gene Name: PDGFRA

Molecule-Related Drug & Molecule List

4 Approved Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avapritinib	DMK2GZX	Gastrointestinal stromal tumour	2B5B	Approved	[1]
Olaratumab	DMNYOIX	Soft tissue sarcoma	2B57	Approved	[2]
Ripretinib	DM958QB	Gastrointestinal stromal tumour	2B5B	Approved	[3]
Romiplostim	DM3U7SZ	Thrombocytopenia	3B64	Approved	[4]

6 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CP-868596	DMZIM37	Gastrointestinal cancer	2C11	Phase 3	[5]
E-3810	DM42PFT	Solid tumour/cancer	2A00-2F9Z	Phase 3	[6]
Famitinib	DMSFWT7	Solid tumour/cancer	2A00-2F9Z	Phase 2	[7]
MEDI-575	DMI9WVM	Glioblastoma multiforme	2A00.0	Phase 2	[8]
MP470	DMELUAK	Solid tumour/cancer	2A00-2F9Z	Phase 2	[9]
XL-820	DMMHX9K	Solid tumour/cancer	2A00-2F9Z	Phase 2	[10]

6 Patented Agent(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PMID28460551-Compound-1	DMHV75N	Breast cancer	2C60-2C65	Patented	[11]
Pyridine derivative 18	DMBZMYT	N. A.	N. A.	Patented	[12]
Pyridine derivative 19	DMXYT40	N. A.	N. A.	Patented	[12]
Pyridine derivative 20	DMAOF0W	N. A.	N. A.	Patented	[12]
Pyridine derivative 21	DMF3907	N. A.	N. A.	Patented	[12]
Pyridine derivative 22	DMSIERF	N. A.	N. A.	Patented	[12]

4 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SRI-62-834	DMRKE9G	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 2	[13]
CEP-2563	DMH1PQ0	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[14]
AG1295	DMT10C2	N. A.	N. A.	Terminated	[15]
RG-13022	DMRFYOS	N. A.	N. A.	Terminated	[16]

79 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(1H-indol-2-yl)(5-methoxy-1H-indol-2-yl)methanone	DM21CXZ	Discovery agent	N.A.	Investigative	[15]
(1H-indol-2-yl)(5-phenoxy-1H-indol-2-yl)methanone	DM94XJ2	Discovery agent	N.A.	Investigative	[15]
(1H-indol-2-yl)(6-methoxy-1H-indol-2-yl)methanone	DM7KDNM	Discovery agent	N.A.	Investigative	[15]
(5-fluoro-1H-indol-2-yl)-(1H-indol-2-yl)methanone	DMIV4BU	Discovery agent	N.A.	Investigative	[15]
(5-hydroxy-1H-indol-2-yl)(1H-indol-2-yl)methanone	DMPBNYM	Discovery agent	N.A.	Investigative	[15]
1-Phenyl-1H-benzoimidazol-5-ol	DMGV6BI	Discovery agent	N.A.	Investigative	[17]
1-Phenyl-1H-benzoimidazole	DM8YPH0	Discovery agent	N.A.	Investigative	[17]
3-((E)-Styryl)-quinoline	DMAO64J	Discovery agent	N.A.	Investigative	[16]
3-(1H-Indol-3-yl)-6,7-dimethoxy-quinoline	DMSGCKU	Discovery agent	N.A.	Investigative	[16]
3-(1H-Indol-3-yl)-quinoline	DMW7XN5	Discovery agent	N.A.	Investigative	[16]
3-(2-Cyclohexyl-ethyl)-6,7-dimethoxy-quinoline	DMVUK96	Discovery agent	N.A.	Investigative	[16]
3-(3,4-Dichloro-phenyl)-6,7-dimethoxy-quinoline	DMEJH13	Discovery agent	N.A.	Investigative	[16]
3-(3,4-Difluoro-phenyl)-6,7-dimethoxy-quinoline	DMX3AMB	Discovery agent	N.A.	Investigative	[16]
3-(3,4-Dimethoxy-phenyl)-6,7-dimethoxy-quinoline	DMDU10A	Discovery agent	N.A.	Investigative	[16]
3-(3-Fluoro-phenyl)-6,7-dimethoxy-quinoline	DM0ZHJQ	Discovery agent	N.A.	Investigative	[16]
3-(4-Fluoro-phenyl)-6,7-dimethoxy-quinoline	DM0POH2	Discovery agent	N.A.	Investigative	[16]
3-Benzyloxy-6,7-dimethoxy-quinoline	DMPG315	Discovery agent	N.A.	Investigative	[16]
3-Cyclohexylethynyl-6,7-dimethoxy-quinoline	DMCQ6J8	Discovery agent	N.A.	Investigative	[16]
3-Cyclopent-1-enyl-6,7-dimethoxy-quinoline	DM1FSZM	Discovery agent	N.A.	Investigative	[16]
3-Cyclopentyl-6,7-dimethoxy-quinoline	DMS7B6T	Discovery agent	N.A.	Investigative	[16]
3-Pyridin-3-yl-quinoline-6,7-diol	DM60Q1B	Discovery agent	N.A.	Investigative	[16]
3-Pyridin-4-yl-quinolin-7-ol	DM0SEL5	Discovery agent	N.A.	Investigative	[18]
3-Pyridin-4-yl-quinoline	DM6U074	Discovery agent	N.A.	Investigative	[18]
3-Pyridin-4-yl-quinoline-5,7-diol	DMPCT0A	Discovery agent	N.A.	Investigative	[18]
3-Thiophen-3-yl-quinoline	DM9MFZ1	Discovery agent	N.A.	Investigative	[16]
4-(3,4-Dimethoxy-phenoxy)-6,7-dimethoxy-quinoline	DMW1H6C	Discovery agent	N.A.	Investigative	[19]
4-(5-Methoxy-benzoimidazol-1-yl)-phenylamine	DMIWT60	Discovery agent	N.A.	Investigative	[20]
4-(6,7-Dimethoxy-quinolin-3-yl)-benzoic acid	DM8A6UH	Discovery agent	N.A.	Investigative	[16]
4-(6,7-Dimethoxy-quinolin-3-yl)-phenol	DM9RNUX	Discovery agent	N.A.	Investigative	[16]
4-Benzoimidazol-1-yl-phenylamine	DM7AOGD	Discovery agent	N.A.	Investigative	[17]
5,11-Dimethyl-6H-pyrido[4,3-b]carbazol-9-ol	DMWSLTB	Discovery agent	N.A.	Investigative	[21]
5,6,7-Trimethoxy-3-pyridin-4-yl-quinoline	DM53CLY	Discovery agent	N.A.	Investigative	[18]
5,7-Dimethoxy-3-pyridin-4-yl-quinoline	DM724JF	Discovery agent	N.A.	Investigative	[18]
5,7-Dimethoxy-3-thiophen-3-yl-quinoline	DMJAQ41	Discovery agent	N.A.	Investigative	[16]
5,7-Dimethyl-3-thiophen-3-yl-quinoline	DM3P79O	Discovery agent	N.A.	Investigative	[16]
5-(6,7-Dimethoxy-quinolin-3-yl)-1H-pyridin-2-one	DMVMBG0	Discovery agent	N.A.	Investigative	[16]
5-Fluoro-3-thiophen-3-yl-quinoline	DM0OQTJ	Discovery agent	N.A.	Investigative	[16]
5-Methoxy-1-phenyl-1H-benzoimidazole	DMPEKWD	Discovery agent	N.A.	Investigative	[17]
6,7-Dichloro-3-thiophen-3-yl-quinoline	DMJNHSL	Discovery agent	N.A.	Investigative	[16]
6,7-Difluoro-3-thiophen-3-yl-quinoline	DMUZYXQ	Discovery agent	N.A.	Investigative	[16]
6,7-Dimethoxy-3-((E)-styryl)-quinoline	DMSM0QV	Discovery agent	N.A.	Investigative	[16]
6,7-Dimethoxy-3-(2-methoxy-phenyl)-quinoline	DMPYGK9	Discovery agent	N.A.	Investigative	[16]
6,7-Dimethoxy-3-(3-methoxy-phenyl)-quinoline	DMDENVF	Discovery agent	N.A.	Investigative	[16]
6,7-Dimethoxy-3-(4-methoxy-phenyl)-quinoline	DM12DVT	Discovery agent	N.A.	Investigative	[16]
6,7-Dimethoxy-3-(4-nitro-phenyl)-quinoline	DMM7NHI	Discovery agent	N.A.	Investigative	[16]
6,7-Dimethoxy-3-p-tolyl-quinoline	DMM7IAK	Discovery agent	N.A.	Investigative	[16]
6,7-Dimethoxy-3-phenyl-quinoline	DM516B4	Discovery agent	N.A.	Investigative	[16]
6,7-Dimethoxy-3-phenylethynyl-quinoline	DMFRXDT	Discovery agent	N.A.	Investigative	[16]
6,7-Dimethoxy-3-pyridin-3-yl-quinoline	DMSG1AY	Discovery agent	N.A.	Investigative	[16]
6,7-Dimethoxy-3-pyridin-4-yl-quinoline	DMW7K5P	Discovery agent	N.A.	Investigative	[18]
6,7-Dimethoxy-3-thiophen-2-yl-quinoline	DM6WD8T	Discovery agent	N.A.	Investigative	[16]
6-Methoxy-3-pyridin-4-yl-quinoline	DM52SDO	Discovery agent	N.A.	Investigative	[18]
6-Methoxy-3-thiophen-3-yl-quinoline	DMOYL71	Discovery agent	N.A.	Investigative	[16]
7-Chloro-3-pyridin-4-yl-quinoline	DM53A1R	Discovery agent	N.A.	Investigative	[18]
7-Fluoro-3-thiophen-3-yl-quinoline	DM0QI8V	Discovery agent	N.A.	Investigative	[16]
7-Methoxy-3-pyridin-4-yl-quinoline	DMUZIDT	Discovery agent	N.A.	Investigative	[18]
7-Methoxy-3-thiophen-3-yl-quinoline	DM9QKLC	Discovery agent	N.A.	Investigative	[16]
7-Thiophen-3-yl-[1,3]dioxolo[4,5-g]quinoline	DMMU5SO	Discovery agent	N.A.	Investigative	[16]
Benzyl-(6,7-dimethoxy-quinolin-3-yl)-amine	DMFTIMS	Discovery agent	N.A.	Investigative	[16]
Bis-(5-hydroxy-1H-indol-2-yl)-methanone	DMTSEXB	Discovery agent	N.A.	Investigative	[15]
BMS-536924	DMXJB4N	Discovery agent	N.A.	Investigative	[22]
CP-673451	DMVBPRO	Discovery agent	N.A.	Investigative	[23]
D-65476	DM0A54V	Discovery agent	N.A.	Investigative	[24]
Di(1H-indol-2-yl)methanone	DM3DR6J	Discovery agent	N.A.	Investigative	[15]
HKI-9924129	DM5LR2B	Gram-positive bacterial infection	1B74-1G40	Investigative	[25]
JNJ-10198409	DM9GDP5	Discovery agent	N.A.	Investigative	[26]
PD-0166326	DMD2CG9	Discovery agent	N.A.	Investigative	[25]
PD-0173952	DMSCQ9U	Discovery agent	N.A.	Investigative	[25]
PD-0173955	DMOZEW9	Discovery agent	N.A.	Investigative	[25]
PD-0173956	DM8RW92	Discovery agent	N.A.	Investigative	[25]
PD-0173958	DMZQ8YV	Discovery agent	N.A.	Investigative	[25]
PD-0179483	DMKO8LE	Discovery agent	N.A.	Investigative	[25]
PMID21561767C8h	DMABZH6	Discovery agent	N.A.	Investigative	[27]
PMID22765894C8h	DMH5RFU	Discovery agent	N.A.	Investigative	[28]
PP121	DMU8KTO	Discovery agent	N.A.	Investigative	[29]
Ro-4396686	DM5DMCH	Discovery agent	N.A.	Investigative	[30]
RPR-101511	DM0HD3O	Discovery agent	N.A.	Investigative	[16]
RPR-108514A	DM37I92	Discovery agent	N.A.	Investigative	[31]
SU-11652	DMGQXN7	Discovery agent	N.A.	Investigative	[4]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [2] A phase I study of olaratumab, an anti-platelet-derived growth factor receptor alpha (PDGFRalpha) monoclonal antibody, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):595-604.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [4] Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel... J Med Chem. 2003 Mar 27;46(7):1116-9.
• [5] The FLT3 and PDGFR inhibitor crenolanib is a substrate of the multidrug resistance protein ABCB1 but does not inhibit transport function at pharmacologically relevant concentrations.Invest New Drugs.2015 Apr;33(2):300-9.
• [6] E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011 Feb 15;71(4):1396-405.
• [7] Metabolism and bioactivation of famitinib, a novel inhibitor of receptor tyrosine kinase, in cancer patients. Br J Pharmacol. 2013 Apr;168(7):1687-706.
• [8] Clinical pipeline report, company report or official report of MedImmune (2011).
• [9] Phase 1B study of amuvatinib in combination with five standard cancer therapies in adults with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Jul;74(1):195-204.
• [10] National Cancer Institute Drug Dictionary (drug id 452042).
• [11] Cancer stem cell (CSC) inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jul;27(7):753-761.
• [12] RET kinase inhibitors: a review of recent patents (2012-2015).Expert Opin Ther Pat. 2017 Jan;27(1):91-99.
• [13] Antitumor activity of SRI 62-834, a cyclic ether analog of ET-18-OCH3. Lipids. 1987 Nov;22(11):884-90.
• [14] Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov;22(4):449-58.
• [15] Novel bis(1H-indol-2-yl)methanones as potent inhibitors of FLT3 and platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 2006 Jun 1;49(11):3101-15.
• [16] A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline derivatives. J Med Chem. 1994 Jul 8;37(14):2129-37.
• [17] Structure-activity relationships for 1-phenylbenzimidazoles as selective ATP site inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1998 Dec 31;41(27):5457-65.
• [18] 5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyro... J Med Chem. 1994 Aug 19;37(17):2627-9.
• [19] A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
• [20] Structure-activity relationships for 5-substituted 1-phenylbenzimidazoles as selective inhibitors of the platelet-derived growth factor receptor. J Med Chem. 1999 Jul 1;42(13):2373-82.
• [21] Molecular modeling of wild-type and D816V c-Kit inhibition based on ATP-competitive binding of ellipticine derivatives to tyrosine kinases. J Med Chem. 2005 Oct 6;48(20):6194-201.
• [22] Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitum... J Med Chem. 2005 Sep 8;48(18):5639-43.
• [23] Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451. Cancer Res. 2005 Feb 1;65(3):957-66.
• [24] Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. J Med Chem. 2002 Feb 28;45(5):1002-18.
• [25] Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98.
• [26] (6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad ant... J Med Chem. 2005 Dec 29;48(26):8163-73.
• [27] Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett. 2011 Jun 15;21(12):3743-8.
• [28] The design, synthesis, and biological evaluation of potent receptor tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2012 Aug 1;22(15):4979-85.
• [29] Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9.
• [30] Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3.
• [31] The synthesis and SAR of new 4-(N-alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)aminopyrazolo[3,4-d]pyrimidines, inhibitors of CSF-1R tyrosine kinase activity, Bioorg. Med. Chem. Lett. 7(4):421-424 (1997).